Two experts in genetic medicines, Devan Shah and Michelle Lynn Hall, discuss the recently announced federal funding cuts for mRNA research and what it means for this area of science going forward
They explain the size and depth of the cuts, and how it will affect research on both respiratory and non-respiratory conditions. Plus, what it means for global competitiveness for the United States going forward.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from The Studio at Kendall Square
Reverb Therapeutics Co-Founder & CEO David de Graaf and antibody expert Jonathan Davis discuss the science of bispecifics and multispecifics and what the future holds for these modalities
AI Proteins Founder & CEO Chris Bahl and Dana-Farber Cancer Institute Investigator Nick Polizzi discuss the current state of protein design and new innovations that are around the corner
Jack Silberstein's startup, Deck Bio, received a "Golden Ticket" award from Servier - he and Servier's Irene Blat discuss how it is just one of many ways larger companies help biotech entrepreneurs
Precision for Medicine CMO Harpreet Singh and Repertoire Immune Medicines CMO Robert Andtbacka discuss oncology clinical trial design, life on the biotech side, and advice for other CMOs
Get summaries like this every morning.
Free AI-powered recaps of The Studio at Kendall Square and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.